### Comment:
Citron just tweeted about shorting ABBV last week because they incorrectly understood comments by the FDA regarding what would theoretically be a threat to one of AbbVie's drugs (at least, it won't affect sales until 2023, and even then, it will only be marginal pressure to their bottom line). The stock dropped 5% this past week, and if they beat earnings, which they should, the stock could pop to over 100.

### REPLY:
5% is basicly flat but thanks for a quality lead

### END.